External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

Leading full-service brokerage firm in Vietnam. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>For 2Q25, Seegene posted revenue of W114.1bn (+14% YoY), broadly in line with the consensus.</li><li>HPV (+21% YoY) and gastrointestinal (+31% YoY) test kits saw solid growth, while respiratory (including COVID-19) test kits (-19% YoY) and other products (+8% YoY; -16% YoY for private label products) underperformed.</li><li>Women’s health and extraction reagent revenues rose 1% and 22% YoY, respectively.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

For 2Q25, Seegene posted revenue of W114.1bn (+14% YoY), broadly in line with the consensus.HPV (+21% YoY) and gastrointestinal (+31% YoY) test kits saw solid growth, while respiratory (including COVID-19) test kits (-19% YoY) and other products (+8% YoY; -16% YoY for private label products) underperformed.Women’s health and extraction reagent revenues rose 1% and 22% YoY, respectively.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Seegene (096530 KQ/Buy)Margins Appear to Have Bottomed; 2H Outlook Remains Encouraging

Seegene Inc

Seegene (096530 KQ/Buy)Margins Appear to Have Bottomed; 2H Outlook Remains Encouraging